Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease
AbstractDry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), and neurosensory abnormalities. Individuals with DED may exhibit a range of clinical signs, including tear instability, reduced tear production, and epithelial disruption, that are driven by different pathophysiological contributors. Those affected often report a spectrum of pain and visual symptoms that can impact physical and mental aspects of health, placing an overall burden on an individual ’s well-being. This cumulative impact of DED on an individual’s activities and on society underscores...
Source: Drugs - April 23, 2024 Category: Drugs & Pharmacology Source Type: research
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
AbstractThe COVID-19 pandemic has resulted in over 772 million confirmed cases, including nearly 7 million deaths, according to the World Health Organization (WHO). Leveraging rapid development, accelerated vaccine approval processes, and large-scale production of various COVID-19 vaccines using different technical platforms, the WHO declared an end to the global health emergency of COVID-19 on May 5, 2023. Current COVID-19 vaccines encompass inactivated, live attenuated, viral vector, protein subunit, nucleic acid (DNA and RNA), and virus-like particle (VLP) vaccines. However, the efficacy of these vaccines is diminishing...
Source: Drugs - April 23, 2024 Category: Drugs & Pharmacology Source Type: research
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders
AbstractThe sirtuin family is a heterogeneous group of proteins that play a critical role in many cellular activities. Several degenerative diseases have recently been linked to aberrant sirtuin expression and activity because of the involvement of sirtuins in maintaining cell longevity and their putative antiaging function. Idiopathic pulmonary fibrosis and progressive pulmonary fibrosis associated with systemic autoimmune disorders are severe diseases characterized by premature and accelerated exhaustion and failure of alveolar type II cells combined with aberrant activation of fibroblast proliferative pathways leading t...
Source: Drugs - April 17, 2024 Category: Drugs & Pharmacology Source Type: research
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
ConclusionsThis meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies. (Source: Drugs)
Source: Drugs - April 17, 2024 Category: Drugs & Pharmacology Source Type: research
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
AbstractTopical ruxolitinib 1.5% cream (Opzelura®), a Janus kinase (JAK) inhibitor, is the first treatment to be approved in several countries for use in patients aged ≥ 12 years with non-segmental vitiligo. In the identical phase III TRuE-V1 and TRuE-V2 trials, significantly more ruxolitinib cream recipients were able to achieve statistically significant and clinically meaningful facial and total body repigmentation, as well as reductions in vitiligo noticea bility, compared with vehicle recipients. Efficacy was sustained in longer-term analyses to week 104 of treatment. Ruxolitinib 1.5% cream was generally tolerabl...
Source: Drugs - April 16, 2024 Category: Drugs & Pharmacology Source Type: research
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
AbstractAmong the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sarcoma viral oncogene homolog (KRAS).KRAS mutant NSCLC is a heterogenous group of diseases, different from other oncogene-driven tumors in terms of biology and response to therapies. Despite efforts to develop drugs aimed at inhibitingKRAS or its signaling pathways,KRAS had remained undruggable for decades. The discovery of a small pocket in the binding switch II region ofKRASG12C has revolutionized the treatment ofKRASG12C-mutated NSCLC patients. Sotorasib and adagrasib, directKRASG12C inhibitor...
Source: Drugs - April 16, 2024 Category: Drugs & Pharmacology Source Type: research
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain
AbstractAn oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as norethindrone) acetate [Myfembree® (USA); Ryeqo® (EU)] (hereafter referred to as relugolix combination therapy) has been approved in the USA for the management of moderate to severe pain associated with endometriosis in premenopausal women and in the EU for the symptomatic treatment of endometriosis in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis. The gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix decreases estradiol and progesterone levels, w...
Source: Drugs - April 9, 2024 Category: Drugs & Pharmacology Source Type: research
The Pharmacological Landscape for Fatty Change of the Pancreas
AbstractThe quest for medications to reduce intra-pancreatic fat deposition is now quarter a century old. While no specific medication has been approved for the treatment of fatty change of the pancreas, drug repurposing shows promise in reducing the burden of the most common disorder of the pancreas. This leading article outlines the 12 classes of medications that have been investigated to date with a view to reducing intra-pancreatic fat deposition. Information is presented hierarchically —from preclinical studies to retrospective findings in humans to prospective interventional studies to randomised controlled trials....
Source: Drugs - April 4, 2024 Category: Drugs & Pharmacology Source Type: research
Perfluorohexyloctane Ophthalmic Solution: A Review in Dry Eye Disease
AbstractPerfluorohexyloctane ophthalmic solution (Miebo®) is a single-entity, water-, steroid- and preservative-free, first-in-class semifluorinated alkane that is approved in the USA for the treatment of the signs and symptoms of dry eye disease (DED). DED is often linked with meibomian gland dysfunction (MGD), which causes an excessive evaporation of tears. Perfluorohexyloctane ophthalmic solution stabilizes the lipid layer of the tear film and inhibits tear evaporation by forming a monolayer at the air-liquid interface. In the phase III GOBI and MOJAVE trials in adults with DED associated with MGD, one drop of perfluor...
Source: Drugs - March 30, 2024 Category: Drugs & Pharmacology Source Type: research
Dimdazenil: First Approval
This article summarizes the milestones in the development of dimdazenil leading to this first approval for insomnia. (Source: Drugs)
Source: Drugs - March 28, 2024 Category: Drugs & Pharmacology Source Type: research
Correction: Eplontersen: First Approval
(Source: Drugs)
Source: Drugs - March 28, 2024 Category: Drugs & Pharmacology Source Type: research
Dimdazenil: First Approval
This article summarizes the milestones in the development of dimdazenil leading to this first approval for insomnia. (Source: Drugs)
Source: Drugs - March 28, 2024 Category: Drugs & Pharmacology Source Type: research
Correction: Eplontersen: First Approval
(Source: Drugs)
Source: Drugs - March 28, 2024 Category: Drugs & Pharmacology Source Type: research
